Investing Ideas
/
Australian Pharmaceuticals & Biotech Undervalued based on future growth

Australian Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	CUV Clinuvel Pharmaceuticals	AU$12.46	5.7%	-22.1%	AU$606.9m	AU$28.29	PE17.5x	E26.2%	0.4%

Page 1 of 1